Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

by Tim A. Kanters, Jelena Stevanovic, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, Steven Simoens
Published 2017-05-01

Update of the Dutch manual for costing studies in health care.

by Tim A Kanters, Clazien A M Bouwmans, Naomi van der Linden, Siok Swan Tan, Leona Hakkaart-van Roijen
Published 2017-01-01

Care-related Quality of Life of informal caregivers of the elderly after a hip fracture

by Cornelis L. P. van de Ree, Kari Ploegsma, Tim A. Kanters, Jan A. Roukema, Mariska A. C. De Jongh, Taco Gosens
Published 2018-05-01

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease

by Tim A. Kanters, Ans T. van der Ploeg, Michelle E. Kruijshaar, Dimitris Rizopoulos, W. Ken Redekop, Maureen P. M. H. Rutten-van Mӧlken, Leona Hakkaart-van Roijen
Published 2017-12-01

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study

by Catharina M. Mulders-Manders, Tim A. Kanters, Paul L. A. van Daele, Esther Hoppenreijs, G. Elizabeth Legger, Jan A. M. van Laar, Anna Simon, Leona Hakkaart-van Roijen
Published 2018-04-01